CD274 and non-small cell lung carcinoma: In conclusion, our study showed similar outcomes in patients with NSCLC treated with pembrolizumab and platinum-based chemotherapy in a real-world setting compared to registered clinical trials, regardless of PD-L1 expression and histology.